Navigation Links
EGFR mutation not prognostic factor in non-small cell lung cancer
Date:1/15/2013

DENVER Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence of mutation in the EGFR gene is known as a predictive marker for the response to treatment. However, whether or not these EGFR mutations are prognostic factors for non-small cell lung cancer (NSCLC) has not been known. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes EGFR mutations are not a prognostic factor in surgically resected patients or patients with recurrence treated with conventional therapies. However, after disease recurrence, administration of EGFR tyrosine kinase inhibitors can prolong survival.

A prognostic marker is a patient characteristic or tumor factor that predicts the patient outcome, independent of the treatment. In the study, researchers retrospectively collected a series of samples from patients who underwent surgery whose EGFR mutations status had been tested, then analyzed patient survival. The patients were seen between June 1998 and February 2010 at the Seoul National University Hospital. And after excluding some patients, researchers analyzed data from 863 patients.

They concluded that although the EGFR mutation is a predictive marker for EGFR TKI response, the presence of EGFR mutation is not a prognostic factor in NSCLC.

The researchers believe, "the clinical observation that patients with EGFR mutation seem to survive longer may be because EGFR mutation is more frequently associated with other significant prognostic factors, such as age, stage, or smoking status. On the basis of our results, the pathologic stage seems to affect the prognosis by influencing the cancer recurrence, and smoking status seems to be the most important prognostic factor f
'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1 2

Related biology news :

1. Will a genetic mutation cause trouble? Ask Spliceman
2. BRG1 mutations confer resistance to hormones in lung cancer
3. Researchers reveal how a single gene mutation leads to uncontrolled obesity
4. Genetic mutation found in familial chronic diarrhea syndrome
5. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
6. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
7. Gene mutation identified as contributor to autism spectrum disorders
8. A single stem cell mutation triggers fibroid tumors
9. Common genetic mutation increases sodium retention, blood pressure
10. UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer
11. Gene mutations cause massive brain asymmetry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/14/2015)... DUBLIN , May 14, 2015 Research and ... addition of the "Fingerprint Sensors Market in Smart ... This report believes that 2014 was a watershed ... to Apple,s introduction of ,Apple Pay,. Apple gave fingerprint ... its mobile payment service. Fingerprint sensors are a must-have ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... large-scale expansion of agriculture in the Amazon through deforestation ... study. Published today, 10 May, in IOP Publishing,s ... deforestation will not only reduce the capacity of the ... feedbacks that will decrease the productivity of pasture and ...
... San Diego, CA A large, multi-institutional research team involved ... analysis in the current issue of the journal Cell ... direct early human development. Led by Bing Ren of the ... Institute for Biological Studies and James Thomson of the Morgridge ...
... at St. Jude Children,s Research Hospital, has been selected ... is one of 27 scientists nationwide chosen for the ... HHMI investigators in the United States, and Dyer will ... St. Jude. Investigators selected for the program by ...
Cached Biology News:No-win situation for agricultural expansion in the Amazon 2Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3St. Jude scientist named Howard Hughes Medical Institute investigator 2
(Date:6/1/2015)... 2015 Regis Technologies, Inc. is ... chiral stationary phases (CSPs) for analytical and preparative ... and presenting solutions for new clients, Regis implemented ... valuable addition to its core expertise in chiral ... can tackle projects for the scale clients need–from ...
(Date:6/1/2015)... , ROCHESTER, Minn. and ... 2015 Baxter Ventures, the venture arm of ... Clinic and Velocity Pharmaceutical Development, LLC ("VPD") today announced ... a unique collaboration model initiated by Baxter Ventures to ... in the areas of immunology, hematology, and oncology. Following ...
(Date:6/1/2015)...  Berg, a biopharmaceutical company committed to uncovering health ... from its trials using its cancer drug BPM 31510 ... triple negative breast cancer, at the 51 st ... (ASCO), May 29 – June 2 in ... one of the first cancer drugs guided in development ...
(Date:6/1/2015)... 1, 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... cancer immunotherapies, today announced a collaboration with University ... Medicine to test ImmunoPulse™ IL-12 as an immunotherapy ... goals of the canine study are to advance ... ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
Breaking Biology Technology:Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4
... - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today ... Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced ... Clinical Cancer Research. , , ... The paper covers final results from a Phase Ia/Ib U.K. ...
... , NINGBO, China , ... Equipment Co., Ltd. (TAIJI),s FGD (Flue-gas desulfurization),technology was officially ... For the project, TAIJI chose to use steel slag ... used in desulfurization. In,comparison to the use of lime ...
... May 18, 2010 Simbionix USA Corporation,the world,s leading provider ... industry, is proud to,report that their ANGIO Mentor virtual reality simulator was ... April 2010 for,the training and certification of vascular physicians from medical ... , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research 2Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research 3Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research 4TAIJI Announces Official Operation of Its Sintering FGD Project for Tangshan 2Simbionix ANGIO Mentor Plays Important Role in Physician Training and Certification 2
... Building on over 20 years of ... for the Life Sciences, the Freedom EVO ... for expansion according to future needs. Together ... each system is equipped to successfully operate ...
... fixed-angle microcentrifuge rotor at RCF up ... filters consist of a membrane-containing filter ... filter by centrifugation for bacteria removal, ... of cells from media and DNA ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. Material: ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: